Joyce David L, Conte John V, Russell Stuart D, Joyce Lyle D, Chang David C
Department of Surgery, Johns Hopkins University, Baltimore, Maryland, USA.
J Surg Res. 2009 Mar;152(1):111-7. doi: 10.1016/j.jss.2008.02.065. Epub 2008 Apr 1.
Implantation of a left ventricular assist device (LVAD) has been shown to improve survival and quality of life among selected patients with end-stage heart failure. We hypothesized that utilization of this complex and expensive treatment modality would be influenced by disparities in access to health care.
We reviewed data from the National Inpatient Sample from 2002 to 2003. Patients were included in the study if they were admitted to the hospital with a primary diagnosis of congestive heart failure or cardiogenic shock. Patients older than 85 years of age and those with contraindications to LVAD therapy due to pre-existing medical conditions were excluded from the study. A multivariate logistic regression analysis was performed to determine the influence of patient characteristics (age, gender, race, comorbidities, socioeconomic status, insurance status, and population density of residence) as well as hospital characteristics (academic versus private and geographic region) on LVAD implantation.
A total of 297,866 patients met the inclusion criteria for the study. Only 291 of these patients underwent LVAD implantation. Factors that adversely influenced access to therapy included age >65 (OR = 0.14), female gender (OR = 0.44), black race (OR = 0.29), admission to a non-academic center (OR = 0.16), and geographic region.
LVAD implantation was significantly influenced by disparities in access to treatment. Systematic reform in the delivery of evolving medical technologies to patients is needed to eliminate these disparities.
已证实植入左心室辅助装置(LVAD)可提高特定终末期心力衰竭患者的生存率和生活质量。我们推测这种复杂且昂贵的治疗方式的应用会受到医疗保健可及性差异的影响。
我们回顾了2002年至2003年全国住院患者样本的数据。如果患者因充血性心力衰竭或心源性休克的主要诊断入院,则纳入本研究。85岁以上的患者以及因既往疾病存在LVAD治疗禁忌证的患者被排除在研究之外。进行多因素逻辑回归分析,以确定患者特征(年龄、性别、种族、合并症、社会经济地位、保险状况和居住人口密度)以及医院特征(学术性与私立性以及地理区域)对LVAD植入的影响。
共有297,866名患者符合研究纳入标准。其中只有291名患者接受了LVAD植入。对治疗可及性产生不利影响的因素包括年龄>65岁(比值比[OR]=0.14)、女性(OR=0.44)、黑人种族(OR=0.29)、入住非学术中心(OR=0.16)以及地理区域。
LVAD植入受到治疗可及性差异的显著影响。需要对向患者提供不断发展的医疗技术进行系统性改革,以消除这些差异。